Blocking the IL-6-STAT3 signaling pathway: Potential liver cancer therapy

Future Oncology

Volumn 7, Issue 2, 2011, Pages 161-164

  Liu, Yan ^a,b   Lin, Jiayuh ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hepatocellular carcinoma; IL 6; STAT3

Indexed keywords

INTERLEUKIN 6; SORAFENIB; STAT3 PROTEIN;

CANCER THERAPY; EDITORIAL; HUMAN; IMMUNE RESPONSE; LIVER CANCER; LIVER CELL CARCINOMA; LIVER PROTECTION; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 79952175492     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.183     Document Type: Editorial

References (42)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer DOI: 10.1002/ijc.25516 (2010) (Epub ahead of print).
2. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
3. Kew MC, Dos Santos HA, Sherlock S: Diagnosis of primary cancer of the liver. BMJ 4, 408-411 (1971).
4. Sherman M: Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin. Liver Dis. 25, 143-154 (2005).
5. Wilson JF: Liver cancer on the rise. Ann. Intern. Med. 142, 1029-1032 (2005).
6. El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127, S27-S34 (2004).
7. Amin R, Mishra L: Liver stem cells and TGF-β in hepatic carcinogenesis. Gastrointest. Cancer Res. 2, S27-S30 (2008).
8. Bosch FX, Ribes J, Cleries R, Diaz M: Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 9, 191-211, v (2005).
9. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576 (2007).
10. Plentz RR, Caselitz M, Bleck JS et al.: Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 40, 80-86 (2004).
11. van Gijssel HE, Maassen CB, Mulder GJ, Meerman JH: p53 protein expression by hepatocarcinogens in the rat liver and its potential role in mitoinhibition of normal hepatocytes as a mechanism of hepatic tumour promotion. Carcinogenesis 18, 1027-1033 (1997).
12. Bataller R, Brenner DA: Liver fibrosis. J. Clin. Invest. 115, 209-218 (2005).
13. Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48, 1312-1327 (2008).
14. Newell P, Villanueva A, Llovet JM: Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials. J. Hepatol. 49, 1-5 (2008).
15. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA: Inflammation and liver cancer: new molecular links. Ann. NY Acad. Sci. 1155, 206-221 (2009).
16. Kishimoto T: IL-6: from laboratory to bedside. Clin. Rev. Allergy Immunol. 28, 177-186 (2005).
17. Kishimoto T: Interleukin-6: from basic science to medicine - 40 years in immunology. Annu. Rev. Immunol. 23, 1-21 (2005).
18. Schafer ZT, Brugge JS: IL-6 involvement in epithelial cancers. J. Clin. Invest. 117, 3660-3663 (2007).
19. Gao SP, Mark KG, Leslie K et al.: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117, 3846-3856 (2007).
20. Grivennikov S, Karin E, Terzic J et al.: IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103-113 (2009).
21. Bollrath J, Phesse TJ, von Burstin VA et al.: gp130-mediated STAT3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15, 91-102 (2009).
22. Taub R: Hepatoprotection via the IL-6/STAT3 pathway. J. Clin. Invest. 112, 978-980 (2003).
23. Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG : Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology 43, 474-484 (2006).
24. Wong VW, Yu J, Cheng AS et al.: High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int. J. Cancer 124, 2766-2770 (2009).
25. Giannitrapani L, Cervello M, Soresi M et al.: Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann. NY Acad. Sci. 963, 46-52 (2002).
26. Naugler WE, Sakurai T, Kim S et al.: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121-124 (2007).
27. Kang HS, Cho DH, Kim SS, Pyun KH, Choi I: Antitumor effects of IL-6 on murine liver tumor cells in vivo. J. Biomed. Sci. 6, 142-144 (1999).
28. Karin M: Nuclear factor-κB in cancer development and progression. Nature 441, 431-436 (2006).
29. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL: Resistance to chemotherapy via STAT3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21, 7611-7618 (2002).
30. Wei LH, Kuo ML, Chen CA et al.: Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22, 1517-1527 (2003).
31. Yu H, Kortylewski M, Pardoll D: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7, 41-51 (2007).
32. Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809 (2009).
33. Park EJ, Lee JH, Yu GY et al.: Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208 (2010).
34. Bromberg JF, Wrzeszczynska MH, Devgan G et al.: STAT3 as an oncogene. Cell 98, 295-303 (1999).
35. Lin L, Amin R, Gallicano GI et al.: The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling. Oncogene 28, 961-972 (2009).
36. Zhang B, Zhong DW, Wang QW et al.: Study on correlation of JAK/STAT signal pathway with progression and prognosis in hepatocellular carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 26, 368-370, 373 (2010).
37. Li WC, Ye SL, Sun RX et al.: Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin. Cancer Res. 12, 7140-7148 (2006).
38. Liu Y, Li PK, Li C, Lin J: Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J. Biol. Chem. 285, 27429-27439 (2010).
39. Li J, Piao YF, Jiang Z, Chen L, Sun HB: Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice. World J. Gastroenterol. 15, 2602-2608 (2009).
40. Choudhari SR, Khan MA, Harris G et al.: Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod. Mol. Cancer Ther. 6, 112-121 (2007).
41. Li F, Fernandez PP, Rajendran P, Hui KM, Sethi G: Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 292, 197-207 (2010).
42. Chen KF, Tai WT, Liu TH et al.: Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin. Cancer Res. 16, 5189-5199 (2010).